Friday, 15 Dec 2017

You are here

UAB Researchers Shed Light on Age-Related Osteoporosis

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.

The UAB researchers found that a protein called Cbf-beta plays a critical role in maintaining the bone-producing cells. Furthermore, examination of aged mice showed dramatically reduced levels of Cbf-beta in bone marrow cells, compared to younger mice. They propose, maintaining Cbf-beta may be essential to preventing human age-associated osteoporosis that is due to elevated creation of fat cells.

They believe with aging, progenitor cells stop creating bone-producing cells, and instead create fat cells. Knowledge of this mechanism can provide targets in the search for novel bone-loss therapeutics to treat human osteoporosis with minimal side effects.

The progenitor cells for osteoblasts are bone marrow mesenchymal stem cells. Besides osteoblasts, mesenchymal stem cells can also differentiate into the chondrocyte cells that make cartilage, the myocyte cells that help form muscles and the adipocytes, or fat cells. Thus, the same progenitor cell has four possible tracks of differentiation.

UAB researchers and colleagues focused on the molecular mechanism that controls the lineage commitment switch between the osteoblast and adipocyte tracks. Led by Yi-Ping Li, Ph.D., UAB professor of pathology, and Wei Chen, M.D., UAB associate professor of pathology, they investigated the key role played by Cbf-beta, or core-binding factor subunit beta.

The team led by Li and Chen generated three mouse models by deleting Cbf-beta at various stages of the osteoblast lineage. All three mouse models showed severe osteoporosis with accumulation of fat cells in the bone marrow, a pathology that resembles aged bone from enhanced adipocyte creation.

Bone marrow mesenchymal stem cells and bone cells from the skulls of Cbf-beta-deficient mice showed increased expression of adipocyte genes.

Looking at the mechanism downstream, the researchers found that the loss of Cbf-beta impeded the canonical Wnt signaling pathway, particularly through decreased Wnt10b expression. In nonmutant mice, they found that the protein complex composed of Cbf-beta and the Runx2 transcription factor binds to the Wnt10b promoter to drive Wnt10b expression. The Cbf-beta/Runx2 complex also inhibited expression of the enhancer protein C/EBP-alpha that promotes differentiation of adipocytes.

In addition, the researchers showed that Cbf-beta maintains the osteoblast lineage commitment in two ways -- through the Wnt paracrine pathway to affect nearby cells and through endogenous signaling within the cell to suppress adipogenesis gene expression.

Altogether, this knowledge of the mechanism driven by Cbf-beta can help explain the imbalance in bone maintenance seen in older people.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Knee Surgery Outcomes Worse with Low Education

Reuters reports that patients who live in low-income communities and lack a college education may have worse pain after knee replacement surgery than their more educated neighbors, citing results from a recent study from the Hospital for Special Surgery in NY.

Weight Loss Does Not Protect OA Knees

A new study presented at the Radiological Society of North America (RSNA) shows that obese people with substantial weight loss may significantly slow down the rate of joint space narrowing (cartilage degeneration) in the knee cartilage, but only if they lose weight through diet and exercise or diet alone; excercise alone is insufficient. 

Prevalence of Arthritis Grossly Underestimated

Researchers at the Boston University School of Medicine have published a new report showing that arthritis affected 91 million adults in the US in 2015 or 37% of the poplulation. Their prevalence estimate is 68% higher than previously reported arthritis national estimates. 

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

Osteoporotic Fractures as Back Pain in Older Men

The Journal of Bone and Mineral Research reports that older men with undiagnosed vertebral fractures are likely to report new or worsening back pain. (Citation source bit.ly/2y9rMiZ)